Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug;12(8):1271-3.
doi: 10.3201/eid1208.051127.

Incubation period of hantavirus cardiopulmonary syndrome

Pablo A Vial  1 , Francisca Valdivieso, Gregory Mertz, Constanza Castillo, Edith Belmar, Iris Delgado, Mauricio Tapia, Marcela Ferrés
Affiliations

Incubation period of hantavirus cardiopulmonary syndrome

Pablo A Vial et al. Emerg Infect Dis. 2006 Aug.

Abstract

The potential incubation period from exposure to onset of symptoms was 7-39 days (median 18 days) in 20 patients with a defined period of exposure to Andes virus in a high-risk area. This period was 14-32 days (median 18 days) in 11 patients with exposure for <48 hours.

PubMed Disclaimer

Figures

Figure
Figure
Incubation period for 20 patients in Chile in whom hantavirus cardiopulmonary syndrome caused by Andes virus developed after various periods of exposure. All patients progressed to the cardiopulmonary phase and were hospitalized at the end of the prodrome.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Botten J, Mirowsky K, Ye C, Gottlieb K, Saavedra M, Ponce L, et al. Shedding and intracage transmission of Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus) model. J Virol. 2002;76:7587–94. 10.1128/JVI.76.15.7587-7594.2002 - DOI - PMC - PubMed
    1. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis. 1997;3:95–104. 10.3201/eid0302.970202 - DOI - PMC - PubMed
    1. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39:1307–13. 10.1086/425007 - DOI - PubMed
    1. Hallin GW, Simpson SQ, Crowell RE, James DS, Koster FT, Mertz GJ, et al. Cardiopulmonary manifestations of the hantavirus pulmonary syndrome. Crit Care Med. 1996;24:252–8. 10.1097/00003246-199602000-00012 - DOI - PubMed
    1. Duchin JS, Koster F, Peters CJ, Simpson GL, Tempest B, Zaki R, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. N Engl J Med. 1994;330:949–55. 10.1056/NEJM199404073301401 - DOI - PubMed

Publication types

LinkOut - more resources